ASCLETIS-B (01672) announced that the company's directors have disclosed encouraging preclinical efficacy results for the combination of ASC47, a first-in-class weight loss candidate drug for obesity treatment that reduces weight without muscle loss, with ASC31, a GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual-target agonist peptide. ASC31 is a novel GLP-1R and GIPR dual-target agonist peptide independently developed by Ascletis, demonstrating favorable pharmacokinetic characteristics in non-human primates, along with positive in vitro activity and promising in vivo efficacy in DIO mice. ASC31 represents part of the achievements from Ascletis' proprietary Ultra-Long-Acting Platform (ULAP) for developing novel subcutaneous injection peptides and oral peptides. ASC47 is a fat-targeted, once-monthly subcutaneous injection thyroid hormone receptor β (THRβ) selective small molecule agonist independently developed by Ascletis. ASC47 possesses unique differentiated characteristics, enabling fat targeting to achieve dose-dependent high drug concentrations in adipose tissue. The DIO mouse study aimed to compare the weight loss efficacy of low-dose ASC47 (9 mg/kg, subcutaneous) combined with ASC31 (3 nmol/kg, subcutaneous) versus low-dose ASC47 (9 mg/kg, subcutaneous) combined with tirzepatide (3 nmol/kg, subcutaneous), with a 14-day treatment period. Results showed that ASC47 combined with ASC31 treatment achieved an average weight loss of 44.8% in DIO mice, representing 17.6% more weight loss compared to ASC47 combined with tirzepatide (38.1%) (p=0.02). "Our novel GLP-1R/GIPR dual receptor agonist peptide ASC31 combined with THRβ agonist ASC47 demonstrated excellent weight loss effects in this animal model. This new therapy shows significant differentiation potential compared to marketed weight loss drugs and other investigational candidate drugs," stated Dr. Wu Jinzi, Founder, Chairman of the Board and Chief Executive Officer of Ascletis. "Ascletis is building a robust pipeline of potential obesity therapies covering both small molecules and peptides, and we look forward to sharing more progress in the future."